Huang et al. (2019) identified in glioblastoma that NF-κB/E2F6 (E2F transcription factor 6) was responsible for EGFRvIII-associated temozolomide resistance and E2F6, under the control of the EGFRvIII/AKT/NF-κB pathway, showed a promising therapeutic target for TMZ resistance. The gene discussed is NFKB1; the disease is glioblastoma.